Skip to content
International News, Medical Health Aged Care

Elon Musk’s brain-implant company, Neuralink, is misleading on its promises: RMIT expert.

RMIT University 2 mins read

Professor Dinesh Kumar, Professor, School of Engineering  

Topics: Elon Musk, Neuralink, brain-computer interface, neural tissues, medical advancement 

“Although it is creating a step in the right direction for brain-computer interface (BCI) advancement, Neuralink is making promises that are simply misleading. 

“In terms of technology, Neuralink has gone further than others. The biggest selling point for them is their medical procedure, essentially having a CED scan and robotic surgery built into one.  

"It has also developed a very accurate electrode placement system that won’t compromise blood flow while injecting 1,000 electrodes into the brain. 

“The medical procedure requires extensive surgery with a small part of the skull being cut open and the electronic chip being placed inside. But there are several problems with this.  

“Firstly, infection. Although any surgery has a risk of infection, this is especially worrisome as it is cutting the skull open.  

“But the biggest problem is that the brain has a natural tendency to shut down neurons after there is a change in its structure.  

“The surgery would cause trauma and change the brain’s neurons’ behaviours and positions. 

“Furthermore, there are a lot of extreme risks such as scarring of the neural tissues or interfering with the sensory and motor pathways.  

“There are too many unknowns, and it is very likely than not something will change inside the brain of the user. 

“Certainly, a great development but based on decades of work already done. Researchers in other parts of the globe have been working on such technology for decades.  

“Elon Musk is so confident in the devices’ safety that he would be willing to implant it in his own children. He envisions both disabled and healthy individuals getting these surgical implants. 

“Additionally, Musk mentioned the device could solve a range of conditions such as obesity, depression and schizophrenia. Even going as far as saying it can enable web browsing and telepathy. 

“But it is worth noting that Neuralink is FDA-approved for a clinical trial of the device, not for commercial use. Which is very different.  

“The surgery should only be operated for extreme cases such as individuals who has motor neuron diseases or full paralysis. Not healthy ones.  

“Elon Musk knows how to sell things, and this might be his way to gain further funding. By selling his big vision.  

“I have a suspicion that these clinical trials will only be able to record data that will eventually lead to a commercial product in a few decades. 

“As a scientist, it is a welcome move. But it is simply over-hyped. Neuralink paints itself as the final solution while it still has a long way to go before it can materialise Elon Musk’s promises.” 

Professor Dinesh Kumar is a biomedical signals expert in the School of Engineering at RMIT University, Melbourne. His research focuses on biomedical engineering, bio-signal processing and intelligent systems. He has gained international media coverage for his work.  


Contact details:

Interviews: Dinesh Kumar, 0404 716 543 or dinesh.kumar@rmit.edu.au  

 

General media enquiries: RMIT Communications, 0439 704 077 or news@rmit.edu.au

More from this category

  • Medical Health Aged Care
  • 18/10/2024
  • 10:22
Royal Australian College of GPs

‘Fantastic milestone’ for 88 new specialist GPs in South Australia

The Royal Australian College of GPs will welcome 88 new fellows as specialist GPs in South Australia at a ceremony on Saturday 19 October, which will also celebrate the state’s annual RACGP Award winners. The new GPs attending the event in Adelaide Town Hall will include eight rural generalists – GPs who’ve completed Additional Rural Skills Training in fields such as anaesthesia and obstetrics. Fellowship of the RACGP (FRACGP) reflects a doctor’s qualification and expertise as a specialist GP and is the culmination of around 11 years of education, training, rigorous assessment, and experience in primary care. RACGP President Dr…

  • Medical Health Aged Care, Science
  • 18/10/2024
  • 09:30
Centenary Institute

Revealing the role of immune cells in liver cancer

New research from the Centenary Institute and the University of Sydney has uncovered important insights into the immune environment within liver cancer, the sixth…

  • Contains:
  • Medical Health Aged Care
  • 18/10/2024
  • 06:35
Royal Australian College of GPs

ACT Labor’s proposed walk-in centres expansion leaves cost and care questions unanswered: RACGP

The Royal Australian College of GPs (RACGP) has reiterated its call for the next ACT government to commit to an independent evaluation of the ACT nurse-led walk-in centres. With ACT Labor announcing an expansion of centres which are reportedly bleeding taxpayers’ money, ahead of this Saturday’s election, the RACGP also gave its assessment of parties’ primary care policies. An independent evaluation of the centres has been a core pillar of the RACGP’s ACT election platform since before a Canberra Times investigation revealed health officials had “buried” $10 million in expenses. Emails obtained under a Canberra Times freedom of information request…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.